Barclays
STOK icon

Barclays’s Stoke Therapeutics STOK Stock Holding History

Barclays’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$478K Buy
14,606
+4,487
+44% +$144K ﹤0.01% 3256
2026
Q1 		$329K Sell
10,119
-140,826
-93% -$4.62M ﹤0.01% 3428
2025
Q4 		$4.79M Buy
150,945
+43,222
+40% +$1.3M ﹤0.01% 2250
2025
Q3 		$2.53M Sell
107,723
-32,177
-23% -$551K ﹤0.01% 2708
2025
Q2 		$1.59M Buy
139,900
+71,539
+105% +$679K ﹤0.01% 3031
2025
Q1 		$455K Sell
68,361
-11,751
-15% -$110K ﹤0.01% 3586
2024
Q4 		$884K Buy
80,112
+372
+0.5% +$4.57K ﹤0.01% 3456
2024
Q3 		$980K Buy
79,740
+47,239
+145% +$669K ﹤0.01% 3372
2024
Q2 		$439K Buy
32,501
+11,877
+58% +$160K ﹤0.01% 3116
2024
Q1 		$278K Sell
20,624
-18,647
-47% -$113K ﹤0.01% 3934
2023
Q4 		$207K Buy
39,271
+30,831
+365% +$132K ﹤0.01% 4403
2023
Q3 		$33.3K Sell
8,440
-6,389
-43% -$42K ﹤0.01% 4026
2023
Q2 		$158K Sell
14,829
-8,031
-35% -$85.4K ﹤0.01% 3365
2023
Q1 		$190K Buy
22,860
+4,417
+24% +$39.9K ﹤0.01% 3817
2022
Q4 		$170K Buy
18,443
+7,880
+75% +$81.9K ﹤0.01% 3936
2022
Q3 		$135K Buy
10,563
+642
+6% +$10.2K ﹤0.01% 3397
2022
Q2 		$131K Buy
9,921
+5,236
+112% +$79.5K ﹤0.01% 3658
2022
Q1 		$98K Sell
4,685
-18,484
-80% -$370K ﹤0.01% 3790
2021
Q4 		$556K Buy
23,169
+14,000
+153% +$334K ﹤0.01% 3159
2021
Q3 		$233K Sell
9,169
-1,844
-17% -$51.4K ﹤0.01% 3540
2021
Q2 		$370K Sell
11,013
-6,634
-38% -$235K ﹤0.01% 3243
2021
Q1 		$686K Buy
17,647
+12,514
+244% +$712K ﹤0.01% 3001
2020
Q4 		$318K Sell
5,133
-1,682
-25% -$77.1K ﹤0.01% 3520
2020
Q3 		$229K Sell
6,815
-3,166
-32% -$90.4K ﹤0.01% 3759
2020
Q2 		$239K Buy
9,981
+3,783
+61% +$89.8K ﹤0.01% 3929
2020
Q1 		$142K Sell
6,198
-3,638
-37% -$89.9K ﹤0.01% 4539
2019
Q4 		$278K Buy
9,836
+3,835
+64% +$96.5K ﹤0.01% 4778
2019
Q3 		$129K Buy
6,001
+5,087
+557% +$142K ﹤0.01% 5295
2019
Q2 		$27K Buy
+914
New +$24.5K ﹤0.01% 6338

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Barclays's STOK Position: Q2 2026 in Review

Barclays increased its Stoke Therapeutics (STOK) stake by 44% in Q2 2026, buying an estimated $144K and bringing the position to 14,606 shares worth $478K. The position accounts for ﹤0.01% of the portfolio, ranked #3256.

Barclays first reported a position in STOK in Q2 2019 and has held it in 29 quarters since. The position peaked at $4.79M in Q4 2025. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Barclays held 14,606 shares of Stoke Therapeutics worth $478K as of Q2 2026.
  • Barclays bought 4,487 Stoke Therapeutics shares in Q2 2026, an estimated $144K.
  • Stoke Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3256 holding.
  • Barclays first reported a position in Stoke Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • Barclays's Stoke Therapeutics position peaked at $4.79M in Q4 2025.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.